scPharmaceuticals Inc SCPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
-
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
-
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
-
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
-
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
-
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Trading Information
- Previous Close Price
- $4.42
- Day Range
- $4.46–4.75
- 52-Week Range
- $3.24–7.15
- Bid/Ask
- $4.21 / $4.99
- Market Cap
- $230.63 Mil
- Volume/Avg
- 211,285 / 271,133
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.45
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 96
Comparables
Valuation
|
Metric
|
SCPH
|
HRTX
|
ARCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 8.41 |
Price/Book Value | 18.01 | — | 2.30 |
Price/Sales | 7.45 | 2.25 | 4.02 |
Price/Cash Flow | — | — | — |
Price/Earnings
SCPH
HRTX
ARCT
Financial Strength
|
Metric
|
SCPH
|
HRTX
|
ARCT
|
|---|---|---|---|
Quick Ratio | 3.45 | 1.76 | 3.10 |
Current Ratio | 4.84 | 2.38 | 3.78 |
Interest Coverage | −6.70 | — | −3,734.00 |
Quick Ratio
SCPH
HRTX
ARCT
Profitability
|
Metric
|
SCPH
|
HRTX
|
ARCT
|
|---|---|---|---|
Return on Assets (Normalized) | −64.80% | −11.68% | −9.87% |
Return on Equity (Normalized) | −161.87% | — | −15.36% |
Return on Invested Capital (Normalized) | −71.67% | −18.15% | −18.47% |
Return on Assets
SCPH
HRTX
ARCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ffqjkhkh | Xrh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jlfcvzkh | Qtbqds | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pwqmljvy | Sqpnqws | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qddvjrd | Xvfsctp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Mkgtrgy | Znpy | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xnqwlgt | Tsyp | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ypxbsllp | Cbk | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xtjfjfr | Xcyn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rxfsdjbl | Sxdgjk | $13.4 Bil | |||
| Incyte Corp
INCY
| Jpfdjddf | Xmwbsdg | $12.7 Bil |
United States